Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 4/20 | 0.37 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409241 | 0.87 | ALDH1A1 (0.45) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL21230708 | 0.87 | CYP4F2 (0.46) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL19637212 | 0.85 | CYP4F2 (0.44) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL18135223 | 0.85 | CYP4F2 (0.44) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL31585725 | 0.85 | LMNA (0.45) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL25287787 | 0.85 | ALDH1A1 (0.45) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL21216428 | 0.85 | RXRA (0.46) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL21195792 | 0.85 | CYP4F2 (0.52) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL31105959 | 0.85 | ALDH1A1 (0.45) | ALDH1A1POLBLMNACYP4F2CYP4A11 | |
| SCHEMBL25787278 | 0.84 | CYP4F2 (0.43) | ALDH1A1POLBLMNACYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242880-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE | MY-T BIO LIMITED (GB) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025215188-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PKMYT1 | MY-T BIO LIMITED (GB) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025106014-A1 | COMPOUNDS AND METHODS FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2025-05-22 | — | — | WO | disclosed |
| CN-119977960-A | Cyano-substituted heteroaromatic ring derivatives, pharmaceutical compositions containing same, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025007784-A1 | HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119156388-A | Membrane associated tyrosine and threonine kinase inhibitors | 海南先声再明医药股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2024249817-A1 | TRICYCLIC PKMYT1 KINASE INHIBITORS | ENLIVEN INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118791480-A | Heteroaromatic ring compounds and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024184520-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| CN-118239947-A | Compound, intermediate, preparation method, pharmaceutical composition and application | 上海艾力斯医药科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2020-02-27 | — | — | US | disclosed |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2019150305-A1 | SUBSTITUTED QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-10280172-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-06-07 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | ALDH1A1 4028/4885POLB 515/4885LMNA 406/4885 |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | ALDH1A1 4072/4885POLB 2089/4885LMNA 1149/4885 |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | ALDH1A1 4018/4885POLB 523/4885LMNA 411/4885 |
| US-10280172-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | ALDH1A1 4028/4885POLB 515/4885LMNA 406/4885 |
| US-10662204-B2 | Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents | DPYD, PDXK, TYMP | ALDH1A1 2390/4885POLB 358/4885LMNA 2547/4885 |
| US-20190233440-A1 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents | DPYD, TYMP, TOP2A | ALDH1A1 2120/4885POLB 338/4885LMNA 1636/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 4303/4885POLB 2000/4885LMNA 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.